First Trust Direct Indexing L.P. Has $631,000 Stake in argenx SE (NASDAQ:ARGX)

First Trust Direct Indexing L.P. raised its holdings in argenx SE (NASDAQ:ARGX) by 41.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,659 shares of the company’s stock after buying an additional 489 shares during the period. First Trust Direct Indexing L.P.’s holdings in argenx were worth $631,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ARGX. Jennison Associates LLC raised its holdings in argenx by 32.2% during the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock worth $743,219,000 after acquiring an additional 368,367 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of argenx by 339.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock worth $285,925,000 after purchasing an additional 449,151 shares in the last quarter. RTW Investments LP boosted its holdings in shares of argenx by 5.2% in the 3rd quarter. RTW Investments LP now owns 507,195 shares of the company’s stock valued at $249,352,000 after buying an additional 25,000 shares during the last quarter. Invesco Ltd. grew its stake in shares of argenx by 377.0% in the third quarter. Invesco Ltd. now owns 430,787 shares of the company’s stock valued at $211,788,000 after buying an additional 340,482 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of argenx by 7.4% in the fourth quarter. Federated Hermes Inc. now owns 356,507 shares of the company’s stock valued at $135,626,000 after buying an additional 24,416 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the subject of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $521.00 price target on shares of argenx in a research note on Thursday, April 18th. Truist Financial raised their target price on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Wells Fargo & Company lifted their price target on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Wolfe Research initiated coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Scotiabank lifted their target price on argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and an average price target of $528.16.

argenx Stock Down 1.3 %

Shares of ARGX opened at $388.20 on Friday. argenx SE has a 12 month low of $327.73 and a 12 month high of $550.76. The firm’s 50 day moving average is $383.78 and its 200-day moving average is $412.37.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The company had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the company earned ($0.70) EPS. As a group, research analysts anticipate that argenx SE will post -2.09 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.